Recent studies report that NQO1 is upregulated in NSCLC in contrast to adjacent non-tumor tissue and is proposed to be a poor prognostic biomarker in stage I-II lung cancer and a potential therapeutic target for NSCLC patients [22]. This evidence concerns the gene NQO1 and lung carcinoma.